Synonyms: SELP, CD62P
Inclacumab (Anti-P-Selectin / CD62p) is a humanized monoclonal IgG4 antibody selectively targets P-selectin. It reduces cell adhesion showing potential for prevention of sickle cell disease (SCD). MW :150 KD.
| Featured Inhibitors | Y-27632 Dihydrochloride SB431542 CHIR-99021 (Laduviglusib) RMC-7977 RMC-6236 (Daraxonrasib) MRTX1133 MG132 Z-VAD-FMK VT3989 IAG933 |
|---|
| Description |
Inclacumab (Anti-P-Selectin / CD62p) is a humanized monoclonal IgG4 antibody selectively targets P-selectin. It reduces cell adhesion showing potential for prevention of sickle cell disease (SCD). MW :150 KD.
|
References |
|---|
| CAS No. | 1256258-86-2 |
|---|---|
| Molecular Weight | 150 |
| Isotype | Human IgG4SP |
| Source | CHO |
| Purification | AKTA |
| Sterility | 0.2 μM filtered |
| Formulation | 100 mM Pro-Ac, 20mM Arg, pH5.0 |
| Storage (From the date of receipt) |
Store the undiluted solution at -20°C in the dark to avoid freeze-thaw cycles. |
*Literature analysis of various clone (for this target) products available on the market shows that Selleck's selected clones are more frequently applied. (data until September 2024)
| NCT Number | Recruitment | interventions | Conditions | Sponsor/Collaborators | Start Date | Phases |
|---|---|---|---|---|---|---|
| NCT05348915 | TERMINATED | Drug: Inclacumab | Sickle Cell Disease; Vaso-occlusive Crisis; Vaso-occlusive Pain Episode in Sickle Cell Disease | Pfizer | 2022-03-29 | PHASE3 |
| NCT04935879 | COMPLETED | Drug: Inclacumab|Drug: Placebo | Sickle Cell Disease; Vaso-occlusive Pain Episode in Sickle Cell Disease; Vaso-occlusive Crisis | Pfizer | 2021-10-04 | PHASE3 |
| NCT04927247 | TERMINATED | Drug: Inclacumab|Drug: Placebo | Sickle Cell Disease; Vaso-occlusive Crisis; Vaso-occlusive Pain Episode in Sickle Cell Disease | Pfizer | 2021-12-09 | PHASE3 |
| NCT01815827 | COMPLETED | Drug: inclacumab | Healthy Volunteer | Hoffmann-La Roche | 2013-06 | PHASE1 |
(data from https://clinicaltrials.gov, updated on 2025-12-17)
Tel: +1-832-582-8158 Ext:3
If you have any other enquiries, please leave a message.